Clinical trial · Interventional
Analgesic Effect of Serratus Plane Block With Adjuvant Agents in Breast Cancer Surgery
Comparison of the Postoperative Analgesic Efficacy of Serratus Plane Block With Different Adjuvant Agents in Breast Cancer Surgery
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pain after breast surgery has been described as moderate to severe in intensity and, if inadequately treated, increases postoperative morbidity, hospital cost, and the incidence of persistent postoperative pain. Serratus anterior plane block is an interfascial injection technique for analgesia of the chest wall. The aim of this study was to investigate the effect of magnesium and dexmedetomidine as adjuvant agents on postoperative analgesia in serratus anterior plane block in patients undergoing modified radical mastectomy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Post Operative Pain | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacain | Drug | — | UNRESOLVED |
| Bupivacaine and Dexmedetomidine ile Blokaj | Drug | — | UNRESOLVED |
| Bupivacaine and Magnesium sulfate | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Group B
- description
- Group B (Blockade with Bupivacaine): 30 mL bupivacaine (0.25%)
- interventionNames
- Drug: Bupivacain
- type
- EXPERIMENTAL
- label
- Group M
- description
- Group M (Bupivacaine+Magnesium Blockade): 30 mL bupivacaine (0.25%) + 500 mg magnesium sulphate
- interventionNames
- Drug: Bupivacaine and Magnesium sulfate
- type
- EXPERIMENTAL
- label
- Group D
- description
- Group D (bupivacaine + dexmedetomidine ile Blokaj): 30 mL bupivacaine (% 0.25) + 1 μg/kg dexmedetomidine.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: - 30-70 years old, ASA I-II-III patient group, * Not hypersensitive to the drugs to be used in the study or to the substances contained in them, * No infection or anatomical deformation at the site of intervention, * No antithrombotic treatment and normal coagulation parameters, * Patients who have the consent of themselves or one of their legal guardians. Exclusion Criteria: * Less than 30 years of age, older than 70 years of age or ASA (American Society of Anaesthesiologists) Classification IV, * Receiving antithrombotic therapy with abnormal coagulation parameters, * Infection or anatomical abnormality at the blockage site,
References
Publications (0)
Data not yet available